Irinotecan Hydrochloride Injection Recall Issued by APP Pharmaceuticals

|

Five lots of Irinotecan Hydrochloride injection, a colon cancer drug, have been recalled after fungus was found floating in some vials.

The Irinotecan Hydrochloride injection recall was announced on March 25 by the FDA and APP Pharmaceuticals, the manufacturer, after three customers reported that they saw particles of foreign material floating in the vials. When the vials were analyzed by APP it was discovered that the material was a fungal microbial contaminant.

Non-sterility or foreign material in chemotherapy products could cause infections, and in some cases could be fatal if injected into a cancer patient whose immune system has been compromised by chemotherapeutic treatments. However, there have been no reports of illness or death in connection to the recalled colon cancer treatment injections.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

The recall affects five lots of Irinotecan Hydrochloride Injection, 100mg/5mL, (20mg/mL), 5mL Single Dose Vial and Irinotecan Hydrochloride Injection, 40mg/2mL, (20mg/mL), 2mL Single Dose Vial. The lot numbers affected by the recall include 870DE00301, 870CZ00301, 870DE00101, 870DE00201 and 870DE00401. Only vials from lot 870DE00301 have been confirmed as being contaminated, but the company says it expanded the recall to include lots produced immediately before and after that one at the urging of the FDA out of an abundance of caution.

Irinotecan Hydrochloride injection is approved by the FDA for the treatment of patients suffering from colorectal cancer that has either recurred or failed to respond initial therapy. One side effect of Irinotecan Hydrochloride is that it can lower the number of white blood cells in a patient’s body, due to bone marrow depression. This can cause the patient to become more susceptible to infections.

APP Pharmaceuticals sent out a Dear Healthcare Professional letter (pdf) on March 22 informing healthcare providers of the problem. The fungus was sent out to two genetics testing laboratories but has, so far, not been identified.


0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Parties involved in a Dupixent T-cell lymphoma wrongful death lawsuit will participate in an initial status conference in early December, to map out how the litigation will move forward.
A group of plaintiffs are asking a panel of federal judges to consolidate all Lyft lawsuits involving driver sexual assaults against passengers before one judge as part of a Lyft MDL.
Federal regulators warned years ago that mesh implants were never approved for use in breast surgery, yet manufacturers continued marketing them as internal bra devices for reconstruction and cosmetic augmentation.